Could your own tumor cells beat melanoma? new trial tests immune cell therapy
NCT ID NCT05098184
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a therapy made from a patient's own tumor-fighting immune cells (TILs) for advanced melanoma. Doctors take TILs from a tumor sample, grow them in the lab, and infuse them back after a short chemotherapy course. The study aims to see if this approach is safe and can shrink tumors in 50 people who have not responded to standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tumor-infiltrating lymphocytes (TILs)
What this could lead to
If successful, this could offer a new treatment option for advanced melanoma patients who have run out of standard therapies.
What could go wrong
This is a very early, small trial (50 people) focused on safety. The treatment may not shrink tumors, and side effects from the lymphodepletion regimen can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Tenth People's Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-••••
Contact Email: •••••@•••••